Dennis N. Berman
Director · Inhibikase Therapeutics, Inc.
Individual
- 2025
- Jul 31, 2026
- 3
Other insiders active in the same stocks
Insiders who reported open-market trades in the last 12 months at the companies Dennis N. Berman files at. Multiple unrelated insiders buying the same stock within a short window, cluster buying, has historically been one of the strongest Form 4 signals.
- Sands Capital Life Sciences Pulse Fund II, L.P. - $3.00M in IKT purchases and sales in the last 12 months
More insiders (A-Z)
Browse nearby insider profiles in alphabetical order.
Frequently asked questions
Who is Dennis N. Berman?
Dennis N. Berman is a corporate insider, tracked as Director of Inhibikase Therapeutics, Inc. (IKT). InsiderAlpha holds 3 primary Form 4 filings for them, the earliest from 2025, updated as new SEC EDGAR filings are processed.
How many SEC Form 4 filings has Dennis N. Berman submitted recently?
1 primary Form 4 filing in the last 90 days, covering 1 company.
